• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    4/16/24 4:31:56 PM ET
    $CLNN
    $CYCC
    $DYNT
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email

    Gainers

    • Clene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million.
    • Talphera (NASDAQ:TLPH) shares moved upwards by 11.65% to $1.15. The company's market cap stands at $19.5 million.
    • Lexaria Bioscience (NASDAQ:LEXX) stock moved upwards by 8.22% to $2.5. The market value of their outstanding shares is at $32.2 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock increased by 7.14% to $1.8. The market value of their outstanding shares is at $2.3 million.
    • IGC Pharma (AMEX:IGC) shares rose 6.99% to $0.52. The company's market cap stands at $34.3 million.
    • SHL Telemedicine (NASDAQ:SHLT) stock increased by 6.94% to $5.39. The market value of their outstanding shares is at $88.3 million.

    Losers

    • Telesis Bio (NASDAQ:TBIO) shares fell 15.9% to $0.31 during Tuesday's after-market session. The company's market cap stands at $9.2 million.
    • Dynatronics (NASDAQ:DYNT) stock decreased by 14.53% to $0.47. The market value of their outstanding shares is at $2.2 million.
    • Ontrak (NASDAQ:OTRK) stock decreased by 13.29% to $0.4. The market value of their outstanding shares is at $16.9 million. As per the news, the Q4 earnings report came out today.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 12.35% to $1.42.
    • PaxMedica (NASDAQ:PXMD) shares fell 9.75% to $0.6. The market value of their outstanding shares is at $4.4 million.
    • Longeveron (NASDAQ:LGVN) stock declined by 9.35% to $3.2. The company's market cap stands at $10.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN
    $CYCC
    $DYNT
    $IGC

    CompanyDatePrice TargetRatingAnalyst
    Talphera Inc.
    $TLPH
    1/28/2025$4.00Buy
    Rodman & Renshaw
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    Clene Inc.
    $CLNN
    10/4/2022Outperform → Perform
    Oppenheimer
    Cyclacel Pharmaceuticals Inc.
    $CYCC
    7/18/2022$17.00Outperform
    Oppenheimer
    Clene Inc.
    $CLNN
    7/18/2022$16.00Buy
    H.C. Wainwright
    Clene Inc.
    $CLNN
    5/2/2022$10.00Buy
    Canaccord Genuity
    Ontrak Inc.
    $OTRK
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    More analyst ratings

    $CLNN
    $CYCC
    $DYNT
    $IGC
    SEC Filings

    View All

    SEC Form EFFECT filed by Talphera Inc.

    EFFECT - TALPHERA, INC. (0001427925) (Filer)

    4/2/26 12:15:30 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B7 filed by Talphera Inc.

    424B7 - TALPHERA, INC. (0001427925) (Filer)

    4/1/26 4:37:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - IGC Pharma, Inc. (0001326205) (Filer)

    3/30/26 5:43:01 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

    SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.Poster Presentation 1Title:  A Randomized, Placebo-Controlled, Multi-Center Study Of The Safety And Efficacy Of Niyad In Patients Undergoing Continuous Renal Replacement Therapy (CRRT) Who Cannot Tolerate Heparin Or Are At A Higher Risk of Ble

    3/25/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 millionAll 12 clinical study sites now able to enroll patients to support an expected study completion in 2026Cash and investments of $20.4 million at December 31, 2025Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ETSAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter

    3/23/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Ontrak with a new price target

    ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

    12/5/23 8:03:01 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:25:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Angotti Vincent J.

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:10:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Asadorian Raffi

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:09:19 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aslam Shakil

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:08:02 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $CYCC
    $DYNT
    $IGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care